HK:1801 Stock Latest News
PremiumThe FlyInnovent Biologics announces multiple mechanism-of-action analyses of mazdutide Innovent Biologics announces first participant dosed in Phase 3 GLORY-OSA Innovent Biologics’ New Drug Application for Advanced Renal Cell Carcinoma Accepted in China PremiumCompany AnnouncementsInnovent Biologics Announces Board of Directors Composition Innovent Biologics Updates Nomination Committee Terms Innovent Biologics: Strong Financial Performance and Promising Growth in Oncology and Beyond PremiumCompany AnnouncementsInnovent Biologics Schedules Board Meeting to Approve Annual Results Innovent Biologics Achieves Milestone with Priority Review for Cancer Treatment Innovent Biologics Achieves Strong Revenue Growth and Plans Major Expansions in 2025